{"title":"Aurora kinase inhibitors: an updated patent review (2021-present).","authors":"Yao-Sheng Zhang, Hong-Yu Zhang, Junmin Zhang, Shi-Wu Chen","doi":"10.1080/13543776.2026.2733162","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Aurora kinases are a family of serine/threonine kinases, responsible for regulating mitotic progression and their dysfunction is closely correlated with tumorigenesis. Since its discovery in the late 1990s, Aurora kinase has been established as a promising anti-tumor target.</p><p><strong>Areas covered: </strong>We have updated the clinical trial and patent information for Aurora kinase inhibitors from 2021 to the present, using PubMed, Web of Science, Espacenet Patent Search and www.clinicaltrials.gov for retrieval.</p><p><strong>Expert opinion: </strong>Selective Aurora kinase inhibitors, multi-target inhibitors or combination therapy currently represent the main development trends of Aurora kinase inhibitors. Improving pharmacokinetic properties, enhancing in <i>vivo</i> delivery efficiency and expanding the applications of Aurora kinase inhibitors beyond the antitumor field constitute the latest advances in the research of Aurora kinase inhibitors in recent years.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-17"},"PeriodicalIF":4.7000,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2026.2733162","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Aurora kinases are a family of serine/threonine kinases, responsible for regulating mitotic progression and their dysfunction is closely correlated with tumorigenesis. Since its discovery in the late 1990s, Aurora kinase has been established as a promising anti-tumor target.
Areas covered: We have updated the clinical trial and patent information for Aurora kinase inhibitors from 2021 to the present, using PubMed, Web of Science, Espacenet Patent Search and www.clinicaltrials.gov for retrieval.
Expert opinion: Selective Aurora kinase inhibitors, multi-target inhibitors or combination therapy currently represent the main development trends of Aurora kinase inhibitors. Improving pharmacokinetic properties, enhancing in vivo delivery efficiency and expanding the applications of Aurora kinase inhibitors beyond the antitumor field constitute the latest advances in the research of Aurora kinase inhibitors in recent years.
Aurora激酶是一个丝氨酸/苏氨酸激酶家族，负责调节有丝分裂进程，其功能障碍与肿瘤发生密切相关。自20世纪90年代末被发现以来，极光激酶已被确立为一种有前景的抗肿瘤靶点。涵盖领域：我们已经更新了从2021年至今的极光激酶抑制剂的临床试验和专利信息，使用PubMed， Web of Science， Espacenet专利检索和www.clinicaltrials.gov进行检索。专家意见：选择性极光激酶抑制剂、多靶点抑制剂或联合治疗是目前极光激酶抑制剂的主要发展趋势。改善极光激酶抑制剂的药代动力学性质，提高体内给药效率，将其应用范围扩大到抗肿瘤领域以外，是近年来极光激酶抑制剂研究的最新进展。
期刊介绍：
Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature.
The Editors welcome:
Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area
Patent Evaluations examining the aims and chemical and biological claims of individual patents
Perspectives on issues relating to intellectual property
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
